Photothermal therapy, combined with chemotherapy, holds
promising
prospects for the therapeutic outcome of malignant tumors. However,
the synergistic therapeutic effect suffers from low coloading capacity
and inefficient synchronous tumor-targeting delivery of chemodrug
and photothermal photosensitizers. Herein, we designed a versatile
carrier-free nanoplatform to seek improvement for chemo-photothermal
therapy. An NIR photosensitizer IR-808 was used for noninvasive cancer
imaging, diagnosis, and imaging-guided photothermal therapy. A reduction-sensitive
paclitaxel prodrug (PTX-SS-PEG2k) was rationally synthesized
by covalently linking paclitaxel with polyethylene glycol 2000 via
a disulfide bond. Then, the carrier-free nanoassemblies were constructed
with an inner core of IR-808 and an amphiphilic paclitaxel prodrug
shell. PTX-SS-PEG2k served as a stabilizer and chemodrug
and could facilitate the self-assembly of IR-808 nanoparticles with
high coloading efficiency and reduction-sensitive drug release. The
versatile nanoplatform exhibited multiple advantages, including high
drug payload, reduction-sensitive drug release, tumor-targeting drug
delivery, and potent synergistic antitumor effect. We provide a versatile
theranostic nanoplatform, which improves the effectiveness of synergetic
chemo-photothermal therapy and reduces the off-target toxicity.